Intractable Pain in Advanced Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

According to specific studies, patients with a history of upper urinary tract infections and those who have a low glomerular filtration rate (eGFR) have a higher incidence of UTUC. Urography, the first imaging modality currently used for UTUC screening, offers greater diagnostic accuracy, and many guidelines have only recently been updated to reflect this. Upper urinary tract cancer can be treated in one of two ways. Nephron prophylaxis, also known as conservative treatment, is the preservation of the kidney, either entirely or in part, while minimizing negative effects on kidney function. Using small tools and cameras that can reach the ureters and kidneys and focus only on the tumor, ablation is a technique for eliminating tumors without performing open surgery. Chemotherapy regimens that are frequently used in treating NHL are usually used to treat RS. Usually, the overall response rate of these systems is around 30%. Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone make up the R-CHOP chemotherapy regimen, which is the usual first-line therapy.

Description

Understanding the processes behind pain as well as the behaviour and trajectory of cancer should guide proactive management of cancer pain. In collaboration with pain or palliative medicine doctors, it should make the best use of multimodality approaches and, where necessary, tailored anti-cancer medications. The WHO defines palliative care as the provision of pain management "in conjunction with other therapies that are intended to prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to better understand and manage distressing clinical complications," as well as management of other symptoms, care coordination and advanced care planning, and care of family members.

Intractable Pain in Advanced Cancer (Epidemiology)

With recent medical advancements, there has been a strong focus on the management of chronic pain, which continues to be one of the main causes of functional limitation in patients, poor quality of life, and a costly burden on healthcare. Estimates place the incidence of chronic pain at 37.3% in wealthy nations and 41.1% in developing nations. More than 14 million people were diagnosed with cancer in 2012, and by 2025, it's predicted that number would reach more than 20 million. With better cancer treatment options, more individuals are surviving the disease. One of the terrifying elements of this illness is chronic pain, which is still very difficult to handle at this time. Even while the use of opioids has significantly reduced the discomfort brought on by the disease, chronic pain is still very common.

Intractable Pain in Advanced Cancer -Current Market Size & Forecast Trends

The market for intractable pain management in advanced cancer is projected to grow significantly, with the global cancer pain management market expected to rise from USD 5.25 billion in 2023 to approximately USD 8.39 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.4% during this period. This growth is driven by the persistent and severe pain experienced by cancer patients, necessitating effective management strategies that include medications such as opioids and non-opioid alternatives, as well as complementary therapies like physical therapy and mindfulness practices. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and high prevalence of cancer, while the Asia-Pacific region is expected to be the fastest-growing market, fueled by increasing healthcare investments and rising cancer rates. Overall, the intractable pain management market for advanced cancer is well-positioned for robust expansion through 2035, supported by ongoing innovations in treatment options and a growing emphasis on improving patient quality of life.

The availability of medications and treatment plans for persistent symptoms has improved. Based on current recommendations, medications can be made to treat chemotherapy-related nausea and vomiting. When life expectancy is long enough to realize this benefit, interventions like venting gastrostomy can reduce symptoms related to malignant bowel obstruction. The American Thoracic Society's recommendations are in line with the fact that opiates can reduce refractory dyspnea. Intrathecal pumps and neurolytic blocks are two interventional therapies for intractable pain that have shown promise for controlling symptoms when more conventional treatments have failed. Standard analgesic therapy is ineffective in treating cancer pain in 10% to 30% of cases. For such persistent pain, interventional techniques like peripheral nerve blocks, neuraxial analgesia, and neurolytic blocks may be used. When pain is present in the territory of one or more peripheral nerves, peripheral nerve blocks may be used, but rarely as the primary form of treatment. The effectiveness of intrathecal infusion pumps is called into question by healthcare options and costs, and neuraxial analgesia is a viable option for treating progressive cancer pain. However, because patients frequently experience coexisting somatic and neuropathic pain as well, neurolysis rarely completely eliminates pain. Neurolysis is the targeted destruction of a nerve or nerve plexus using chemicals, radiofrequency ablation (RFA), cryoablation, and neurosurgical procedures. The use of interventional procedures is constrained by the complex medical conditions of palliative patients and the scarcity of high-quality randomized controlled trials. However, some cancer patients gain from interventional treatments that reduce pain and ultimately enhance quality of life.

Report Highlights

Intractable Pain in Advanced Cancer - Current Market Trends

Intractable Pain in Advanced Cancer - Current & Forecasted Cases across the G8 Countries

Intractable Pain in Advanced Cancer - Market Opportunities and Sales Potential for Agents

Intractable Pain in Advanced Cancer - Patient-based Market Forecast to 2035

Intractable Pain in Advanced Cancer - Untapped Business Opportunities

Intractable Pain in Advanced Cancer - Product Positioning Vis-a-vis Competitors' Products

Intractable Pain in Advanced Cancer - KOLs Insight